Skip to main navigation Skip to search Skip to main content

Biotinylated-cationic zinc(II) phthalocyanine towards photodynamic therapy

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Targeting biotin receptors in cancer cells can improve specifying of photosensitizers (PSs) for cancer treatment by photodynamic therapy (PDT) applications. Consequently, there has been extensive research focusing mainly on the design of PSs with optimized pharmaceutical properties and better targeting toward cancer cells. Herein a tailored mono-biotinylated zinc(II) phthalocyanine (Pc-1) substituted with six phenoxy-bis(triazolyl) substituents has been synthesized. This Pc-1 has been further modified to its cationic version (Pc-2) through quaternizing of the triazole moiety to gain water solubility. Both non-ionic zinc(II) phthalocyanine (Pc-1) and its cationic derivative (Pc-2) were characterized by standard spectroscopic techniques, namely; FT-IR, 1H and 13C NMR, UV-Vis and MALDI-TOF, and by elemental analysis. The photophysical and photochemical properties were evaluated in DMSO for the non-ionic Pc-1 and in both DMSO and water for the cationic Pc-2.

Original languageEnglish
Title of host publicationPorphyrin Science By Women (In 3 Volumes)
PublisherWorld Scientific Publishing Co.
Pages587-596
Number of pages10
ISBN (Electronic)9789811223556
DOIs
StatePublished - 1 Jan 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Photochemical
  • Photodynamic therapy (PDT)
  • Photophysical
  • Photosensitizer (PS)
  • Phthalocyanine (PC)

Funding Agency

  • Kuwait Foundation for the Advancement of Sciences

Fingerprint

Dive into the research topics of 'Biotinylated-cationic zinc(II) phthalocyanine towards photodynamic therapy'. Together they form a unique fingerprint.

Cite this